Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06358053
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-10
First Post:
2024-04-02
Brief Title:
CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers
Sponsor:
Corregene Biotechnology Co Ltd
Organization:
Corregene Biotechnology Co Ltd
Study Overview
Official Title:
A Phase I Study to Evaluate the Safety Tolerance and Efficacy of CRTE7A2-01 TCR-T Cells in HLA-A0201 Subjects With HPV16 Positive Advanced Cervical Anal or Head and Neck Cancers and Other Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A single center open single arm dose escalation and dose expansion phase I study to evaluate the safety tolerability and efficacy of CRTE7A2-01 TCR-T cells in HLA-A0201 Subjects HPV16 positive advanced cervical anal or head and neck cancers The study will determine RP2D of CRTE7A2-01 TCR-T cell injection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None